Skip to content

Impact of combination of dexmedetomidine and azasetron on the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery

Impact of combination of dexmedetomidine and azasetron on the prevention of postoperative nausea and vomiting in patients undergoing laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500111699
Enrollment
Unknown
Registered
2025-11-04
Start date
2023-01-03
Completion date
Unknown
Last updated
2025-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

Combination therapy group:The combination therapy group received intravenous injection of 10mg Azasetron combined with 0.5 µ g/kg Dexmedetomidine (the drug was diluted to 20ml with 0.9% sodium and adm
During the operation, propofol 3-6 mg/kg was administered while inhaling 1% -2% sevoflurane to maintain anesthesia.
Control group:The control group received intravenous injection of 10mg Azasetron (administered via a micro infusion pump within 20 minutes), fentanyl 4-6ug/kg, and propofol 3mg/kg for anesthesia induc

Sponsors

Suzhou Ninth Hospital Affiliated to Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age18~65 years; 2. American Society of Anesthesiologists (ASA) physical status I-II; 3.Body mass index (BMI) between 18-30kg/m^2 4.Scheduled for laparoscopic surgery.

Exclusion criteria

Exclusion criteria: 1. Sinus lesion syndrome or severe bradycardia (heart rate<50 beats/min); 2. History of hypertension or cardiac dysfunction; 3.Atrioventricular block of grade II or ? and no pacemaker installed; 4.Left ventricular ejection fraction <40%; 5.History of coronary heart disease or myocardial infarction; 6. Liver or renal dysfunction (Child-Pugh class C or undergoing renal replacement therapy); 7.Parkinson's disease or Alzheimer's disease; 8.Epilepsy or status epilepticus; 9.Pregnancy or lactation; 10.History of chronic pain or preoperative use of sedatives or analgesics; 11.Allergies to medications in this study.

Design outcomes

Primary

MeasureTime frame
Nausea;Vomiting;Visual analogue scale for pain;

Secondary

MeasureTime frame
Heart rate;Blood pressure;Dosage of analgesics for rescue;Dosage for rescue antiemetics;Length of hospital stay;Intraoperative opioid consumption;

Countries

China

Contacts

Public ContactChao Zhang

Suzhou Ninth Hospital Affiliated to Soochow University

ztony1345@gmail.com+86 188 6256 8088

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026